Innoviva Inc (INVA) - Total Assets
Based on the latest financial reports, Innoviva Inc (INVA) holds total assets worth $1.64 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See INVA book value for net asset value and shareholders' equity analysis.
Innoviva Inc - Total Assets Trend (2000–2025)
This chart illustrates how Innoviva Inc's total assets have evolved over time, based on quarterly financial data.
Innoviva Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Innoviva Inc's total assets of $1.64 Billion consist of 44.5% current assets and 55.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 33.7% |
| Accounts Receivable | $34.97 Million | 2.1% |
| Inventory | $39.17 Million | 2.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $182.16 Million | 11.1% |
| Goodwill | $17.91 Million | 1.1% |
Asset Composition Trend (2000–2025)
This chart illustrates how Innoviva Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see INVA company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Innoviva Inc's current assets represent 44.5% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 33.7% of total assets in 2025, up from 0.0% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is intangible assets at 11.1% of total assets.
Innoviva Inc Competitors by Total Assets
Key competitors of Innoviva Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Innoviva Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.64 | 2.35 | 98.04 |
| Quick Ratio | 13.85 | 2.21 | 98.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $677.82 Million | $318.22 Million | $369.13 Million |
Innoviva Inc - Advanced Valuation Insights
This section examines the relationship between Innoviva Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.39 |
| Latest Market Cap to Assets Ratio | 1.02 |
| Asset Growth Rate (YoY) | 25.7% |
| Total Assets | $1.64 Billion |
| Market Capitalization | $1.66 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Innoviva Inc's assets above their book value (1.02x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Innoviva Inc's assets grew by 25.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Innoviva Inc (2000–2025)
The table below shows the annual total assets of Innoviva Inc from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.64 Billion | +25.68% |
| 2024-12-31 | $1.30 Billion | +4.63% |
| 2023-12-31 | $1.24 Billion | +0.98% |
| 2022-12-31 | $1.23 Billion | +32.93% |
| 2021-12-31 | $926.39 Million | -7.32% |
| 2020-12-31 | $999.57 Million | +37.90% |
| 2019-12-31 | $724.83 Million | +32.22% |
| 2018-12-31 | $548.19 Million | +49.23% |
| 2017-12-31 | $367.34 Million | -3.08% |
| 2016-12-31 | $379.00 Million | -10.63% |
| 2015-12-31 | $424.07 Million | -18.71% |
| 2014-12-31 | $521.65 Million | -23.43% |
| 2013-12-31 | $681.25 Million | +84.83% |
| 2012-12-31 | $368.58 Million | +42.43% |
| 2011-12-31 | $258.78 Million | -21.87% |
| 2010-12-31 | $331.20 Million | +82.59% |
| 2009-12-31 | $181.39 Million | -23.19% |
| 2008-12-31 | $236.16 Million | +45.79% |
| 2007-12-31 | $161.98 Million | -38.27% |
| 2006-12-31 | $262.42 Million | +16.72% |
| 2005-12-31 | $224.84 Million | -21.39% |
| 2004-12-31 | $286.02 Million | +128.00% |
| 2003-12-31 | $125.45 Million | -34.90% |
| 2002-12-31 | $192.72 Million | -21.93% |
| 2000-12-31 | $246.85 Million | -- |
About Innoviva Inc
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The com… Read more